AMEX:IMUC - Daily Stock Analysis for ImmunoCellular Therapeutics Ltd

ImmunoCellular Therapeutics Ltd. Daily Stock Analysis

Stock Information

Open 0.24	Close 0.24	High 0.24	Low 0.24	Previous Close 0.24	Daily Price Gain 0.00
YTD High 0.47	YTD High Date Jan 3, 2022	YTD Low 0.14	YTD Low Date Jan 10, 2022	YTD Price Change -0.23	YTD Gain -48.94%
52 Week High 0.80	52 Week High Date Mar 9, 2021	52 Week Low 0.06	52 Week Low Date Mar 23, 2021	52 Week Price Change -0.41	52 Week Gain -63.08%

Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type	Entry Date	Entry Price	Exit Date	Exit Price	Trade Hold Time	Gain	Trade Record
LONG	Jun 9. 2017	11.90	Jun 12. 2017	13.15	1 Trading Days	10.50%	Link
LONG	Jul 3. 2017	9.00	Jul 10. 2017	12.05	4 Trading Days	33.88%	Link
LONG	Aug 22. 2017	3.70	Aug 23. 2017	3.98	1 Trading Days	7.43%	Link
LONG	Sep 13. 2017	3.10	Sep 14. 2017	3.29	1 Trading Days	6.13%	Link
LONG	Sep 22. 2017	3.50	Sep 25. 2017	3.69	1 Trading Days	5.43%	Link
LONG	Sep 27. 2017	3.45	Oct 11. 2017	3.66	10 Trading Days	5.97%	Link
LONG	Mar 2. 2018	2.60	Mar 14. 2018	2.88	8 Trading Days	10.63%	Link
LONG	Sep 24. 2018	2.20	Sep 25. 2018	2.37	1 Trading Days	7.84%	Link

Company Information

Stock Symbol IMUC	Exchange NYSE MKT	Company URL http://www.imuc.com	Company Phone 818-264-2300
CEO Gary S. Titus	Headquarters California	Business Address 23622 CALABASAS ROAD, SUITE 300, CALABASAS, CA 91302
Sector Equity	Industry Category Drugs	Industry Group Biotechnology	CIK 0000822411
About ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.
Description ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

Daily Stock Analysis, IMUC, ImmunoCellular Therapeutics Ltd, priceseries

Legal Information

Useful Links

Contact Us